ClinicalTrials.gg
CompletedNCT04215120DREAM-DUpdated Nov 24, 2021

Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

A Phase 3 interventional study of Desidustat Oral Tablet and Epoetin Alfa in Chronic Kidney Disease Stage 5 on Dialysis, sponsored by Zydus Lifesciences Limited. Completed at 7 sites in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-11-24.

Sponsored by Zydus Lifesciences Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

A phase 3, multicenter, open-label, randomized, active-controlled study to evaluate the efficacy and safety of Desidustat Tablet versus Epoetin alfa Injection for the treatment of anemia in patients with CKD on dialysis. (DREAM-D)

02

Conditions studied

  • Chronic Kidney Disease Stage 5 on Dialysis
03

In context

Lead sponsor

Zydus Lifesciences Limited is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and give for participation. 2. values during the screening period must be 8-11 g/dL (both inclusive).

3.

  1. Patients will be considered not treated with erythropoietin analogue (Epoetin and Darbepoeitin) if they have not received erythropoietin analogue for at least 4 weeks and Mircera® for at least 8 weeks prior to screening visit. OR
  2. Patients who are on ESA therapy must be on stable dose for 4 weeks prior to enrollment (≤30% of dose change).

    1. Patients on hemodialysis (≥2 times in a week) for at least 12 weeks prior to screening visit and have access consisting of an arteriovenous fistula, AV graft, or catheter (permanent/temporary).
    1. Patients with no planned change in dialysis modality and with no planned renal transplant during study period.
    1. ≥40% by echocardiogram prior to randomization.
    1. No iron, folate or Vitamin B12 deficiency.
    1. Females of , must agree to use one of the approved methods, from screening until completion of the follow-up visit.

Exclusion criteria

Exclusion Criteria:

  1. Red blood cell transfusion within 8 weeks prior to participating in the study.
  2. History of previous or concurrent cancer.
  3. Serologic status reflecting active or C infection or (HIV) infection.
  4. Active infection at initiation of study.
  5. History of renal transplant.
  6. Uncontrolled hypertension (defined as SBP >180 mmHg or DBP >100 mmHg) at screening visit (before dialysis).
  7. Patient on high rhEPO dose at screening visit. [High dose defined as an epoetin dose of ≥450 IU/kg/week intravenous or ≥ 300 IU/kg/week subcutaneous or darbepoetin dose of ≥1.5 µg/kg/week subcutaneous].
  8. Major surgery within 90 days of the first day of study drug dosing, and minor surgery within 30 days of the first day of study drug dosing.
  9. Unable to swallow tablets or disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption such as; malabsorption syndrome, resection of the small bowel or poorly controlled inflammatory bowel disease affecting the small intestine.
  10. History of uncontrolled hemolytic anemia, idiopathic thrombocytopenic purpura (ITP) or thalassemia.
  11. Presence or a history of bleeding disorders or clinical conditions (e.g. gastrointestinal [GI] bleeding or constitutional disorders) that may increase risk of life-threatening bleeding.
  12. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  13. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Desidustat or Epoetin alfa or to any erythropoieisis-stimulating agent.
  14. Pregnant and breastfeeding women.
  15. Current life-threatening illness, medical condition or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety.
  16. Other laboratory abnormalities that, in the opinion of the investigator, would compromise the patient's safety or interfere with data interpretation.
  17. Presence of other systemic disorders or diseases (e.g., respiratory, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other body system involvement) which, in the Investigator's opinion, could compromise the patient's safety.
  18. History of significant alcoholism or drug abuse within the past 1 year. History or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco/nicotine products (more than 10 times per day).
  19. History of difficulty with donating blood.
  20. History or presence of any clinically significant (ECG) abnormalities during screening.
  21. Participants who have participated in any drug research study other than the present trial within past 3 months.
  22. Participants who have donated one unit (350 ml) of blood in the past 3 months or history of whole blood transfusion in last 120 days prior to entry in the study.
  23. Existing clinically active chronic inflammatory disease (RA, Celiac disease, UC, Crohns disease)
  24. In case of DM patients, >9%.
  25. Female volunteers with following criteria will not be recruited:

    • History of pregnancy or lactation in the past 3 months
    • Fertile female volunteers not protected against pregnancy by adequate long- term anti-fertility measures
    • History of less than 1 year of menopause and not using adequate long-term anti-fertility measures
    • Positive urine pregnancy test at Visit 2
    • Positive serum β-hCG level at the screening visit
  26. Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any class 3 or 4 cardiac disease as defined by the Functional Classification or history of myocardial infarction prior to first dose with study drug.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
392 participants (actual)

Study arms

  • Active comparator
    Desidustat oral tablet

    Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.

    Drug: Desidustat Oral Tablet

  • Experimental
    Epoetin Injection

    Randomly assigned to receive Epoetin in a 1:1 ratio for 24 weeks.

    Drug: Epoetin Alfa

Interventions

06

What researchers measure

Primary outcomes

  1. Hemoglobin level

    Change in Hb levels from baseline

    Time frame: 24 weeks

Secondary outcomes

  1. Hemoglobin Response

    No. of subjects with Hb response

    Time frame: 24 weeks

  2. Hemoglobin target range

    Time to achieve target range Hb level

    Time frame: 24 weeks

07

Study locations

7 sites
  • Karnavati Hospital Pvt.Ltd
    Ahmedabad, Gujarat 380006, India
  • Shalby Hospital,
    Ahmedabad, Gujarat 380015, India
  • DHS Multispecialty Hospital
    Ahmedabad, Gujarat 380054, India
  • Chopda Medicare & Research Centre Pvt. Ltd
    Nashik, Maharashtra 422005, India
  • Aditya Birla Memorial Hospital
    Pune, Maharashtra 411033, India
  • Eternal Hospital
    Jaipur, Rajasthan 302017, India
  • Star Hospital
    Hyderabad, Telangana 500034, India
08

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Sep 2021, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2019
First posted
Jan 2, 2020
StartActual
Jan 4, 2020
Primary completionActual
Sep 2, 2021
CompletionActual
Sep 2, 2021
Last update
Nov 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04215120
Responsible party
Sponsor
First posted
Jan 2, 2020
Start date
Jan 4, 2020
Primary completion
Sep 2, 2021
Completion
Sep 2, 2021
Last update
Nov 24, 2021

Study contacts

Dr Deven Parmar, MD
study director · Zydus Lifesciences Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion